Background: Obesity is a global epidemic and a complex chronic disease affecting more than one billion patients, leading to severe health issues like diabetes, heart disease, and cancer. While lifestyle changes are the first-line treatment, they are often insufficient. Current medications may cause severe side effects, including muscle loss and vision problems. Objectives: This systematic review aims to generalize and evaluate data from preclinical studies on the effect of flavonoid dihydroquercetin (DHQ) on weight loss in experimental animals compared with placebo-treated animals. Methods: This systematic review was conducted in accordance with the PRISMA guidelines. The protocol was registered in the PROSPERO database in August 2025 (CRD420251129793). Risk of bias (RoB) was assessed by using SYRCLE’s tool. Results: In total, eight studies included in the systematic review involved 175 animals (14 treatment groups and 9 control groups). Calculation of correlations between the reported effect on weight change and initial weight showed a strong association between these rates (R −0.9883). The intensity of DHQ effect depended on the condition: There were strong negative correlations between DHQ dose and the observed effect in diabetes mellitus (R −0.9056), hepatic lipid dysmetabolism (R −0.9339), and hepatic fibrosis (R −0.9025) in mice and rats’ data together. Conclusions: Intake of DHQ in the course of one month and three months resulted in a decrease in animals’ weight by 5.24% ± 1.95% and 18.29% ± 1.96% (p < 0.0001), respectively. Taken together, our results suggest the rationality for further research of DHQ as an anorexigenic agent, focusing on the stereochemistry of this flavonoid and its bioavailability optimization.
20 April 2026 in Problems of Biological, Medical and Pharmaceutical Chemistry
Obesity is a distinct disease that leads to severe health issues like diabetes, heart disease, and cancer. The spread of this pathology can be compared to an epidemic. The search for medications for weight control remains an actual challenge for pharmaceutical and medical sciences. In particular, studying the anorexigenic effect of the flavanol dihydroquercetin (DHQ) is of special interest. Bibliographic databases contain a lot of studies reporting the dynamics of weight changes on the background of taking this flavonoid, and recent studies have shown that DHQ promotes weight loss. Therefore, the aim of this article is to assess the data of experimental studies on the effect of DHQ on the body weight of experimental animal model compared to control groups. The study results demonstrate statistically significant weight loss in mice and rats with various pathologies within the first month of DHQ administration. The biological effect of the flavonoid under the described conditions was comparable to the effect of GLP-1 receptor agonists. Thus, if the results of fundamental research are successfully translated into clinical practice, the use of this flavonoid will make it possible to reduce therapeutic doses of standard medications and will provide administration for patients requiring mild pharmacological intervention. This could improve the life quality of 483 million patients worldwide. Realization of this strategy would reduce the procurement and production of GLP-1 receptor agonists, which, given the high cost of treatment, would reduce the economic burden on the healthcare system. A systematic review identified a number of challenges for pharmaceutical science that require solutions for the successful development of a drug based on DHQ. In particular, future research should focus on studying the influence of flavanonol stereochemistry on its biological effect, as well as on identifying modifications with improved bio-availability and optimal dosage form.
Oral diseases cause a wide range of difficulties for patients. The natural bioactive compound dihydroquercetin (DHQ), which demonstrates regenerative, anti-inflammatory, antioxidative, and antibacterial effects, is of interest for their treatment. The combination of DHQ and l-lysine DHQ is “very easily soluble”. The aim of this study is to compare orally disintegrating tablets based on raw DHQ and on the DHQ-l-lysine composition. Following the guidelines outlined in the ICH Q8 (R2) standard, a fundamental quality target product profile and critical quality attributes were established. The Sediment Delivery Model (SeDeM) method was used to evaluate the substance suitability for direct compression. Quantitative analysis of the DHQ release was carried out by high-performance liquid chromatography, and infrared (IR) spectroscopy was performed using the attenuated total reflection technique without any prior sample preparation. The DHQ-l-lysine composition shows improved dimensions (4.12) and flowability (4.96). The release rate constants (Krelease) were 8.14 and 3.61%/min, while the half-release periods (t50%) were 6.14 and 13.85 min for tablets with DHQ (TF1) and DHQ-l-lysine compositions (TF2), respectively. The difference factor (f1) and similarity factor (f2) were 23.43% and 43.37%, respectively. The tablet manufacture had a critical impact on the characteristics of the IR spectra (the r values −0.8785 and 0.5474 for TF1 and TF2). The conducted study demonstrates the promise of using DHQ-l-lysine composition for developing effective dosage forms with improved technological characteristics and controlled release of the active substance.